KKOYF yields 4.73% · PFE yields 6.13%● Live data
📍 KKOYF pulled ahead of the other in Year 1
Combined, KKOYF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KKOYF + PFE for your $10,000?
Kesko Oyj engages in the grocery trading business in Finland. It operates through Grocery Trade, Building and Technical Trade, and Car Trade segments. The company's Grocery Trade segment is involved in the wholesale and B2B trade of groceries; and the retail sale of the home and specialty goods. This segment operates approximately 1,200 K-food stores, including K-Citymarket, K-Supermarket, K-Market, and Neste K. Its Building and Technical Trade segment engages in the retail, wholesale, and B2B trade of building and home improvement, and electrical and HEPAC products, as well as trades in leisure goods. This segment operates retail store chains under the K-Rauta, K-Bygg, Byggmakker, and Onninen names, as well as leisure goods trade chains under the Intersport and Budget Sport names in Finland, Sweden, Norway, and the Baltic countries. The company's Car Trade segment imports, markets, and retails Volkswagen, Audi, SEAT, CUPRA, Bentley, and Porsche passenger cars, as well as Volkswagen and MAN commercial vehicles in Finland. This segment is also involved in car leasing activities; and the provision of repair and maintenance, spare parts, and accessories services, as well as charging network for electric vehicles under the K-Charge name in Finland. Kesko Oyj was founded in 1940 and is headquartered in Helsinki, Finland.
Full KKOYF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.